Last update 11 Jul 2024

Dexamethasone

Overview

Basic Info

SummaryDexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging. The GR, which is widely distributed across various cell types, is responsible for myriad physiological responses, including immune and inflammatory responses. This small molecule drug, Dexamethasone, binds to the GR, which sends shockwaves of change through gene expression and protein synthesis, consequently giving inflammation and immune system activity a taste of their own medicine.When it comes to treating various conditions, Dexamethasone takes the crown. This potent drug has proved its mettle in treating an impressive range of conditions, including but not limited to actinic cheilitis, light chain (AL) amyloidosis, ocular inflammation, macular edema, and anaphylaxis. Back in the day, on October 30, 1958, the FDA gave the nod to Dexamethasone. It was a time when Merck & Co., Inc., a pharmaceutical company that hailed from the United States, hit the bull's eye with this innovative drug that promised a bright future.
Drug Type
Small molecule drug
Synonyms
Decadron Phosphate, Dexamethasone Intravitreal Implant, DEXTENZA
+ [46]
Target
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC22H29FO5
InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N
CAS Registry50-02-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
JP
25 Aug 2021
Ocular inflammation
US
30 Nov 2018
Ophthalmologic surgical procedures
US
30 Nov 2018
Post procedural inflammation
US
09 Feb 2018
Diabetic macular oedema
EU
26 Jul 2010
Diabetic macular oedema
IS
26 Jul 2010
Diabetic macular oedema
LI
26 Jul 2010
Diabetic macular oedema
NO
26 Jul 2010
Retinal vein occlusion-related macular edema
EU
26 Jul 2010
Retinal vein occlusion-related macular edema
IS
26 Jul 2010
Retinal vein occlusion-related macular edema
LI
26 Jul 2010
Retinal vein occlusion-related macular edema
NO
26 Jul 2010
Uveitis, Posterior
EU
26 Jul 2010
Uveitis, Posterior
IS
26 Jul 2010
Uveitis, Posterior
LI
26 Jul 2010
Uveitis, Posterior
NO
26 Jul 2010
Multiple Myeloma
JP
18 Jun 2010
Retinal Vein Occlusion
US
17 Jun 2009
Nausea and vomiting
JP
15 Sep 2005
Blepharitis
JP
03 Feb 1970
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pain, PostoperativeNDA/BLA
SG
19 Feb 2024
Hospital-acquired pneumoniaPhase 3
FR
15 Feb 2024
PainPhase 3
CN
17 Aug 2023
PainPhase 3
CN
17 Aug 2023
InflammationPhase 3
US
04 Sep 2020
Severe Acute Respiratory SyndromePhase 3
GM
19 Mar 2020
Severe Acute Respiratory SyndromePhase 3
ZA
19 Mar 2020
Severe Acute Respiratory SyndromePhase 3
GB
19 Mar 2020
Breast CancerPhase 3
US
19 Apr 2018
NK-cell lymphomaPhase 3
HK
01 Jul 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
-
prednisolone 250 mg/d
(HD-Pred)
yaiwgimxol(noqgbfjivf) = faaisimize yllpzgouvz (ptexbwmwuv, 28.4 ~ 40.0)
Negative
26 Dec 2024
dexamethasone 40 mg/d
(HD-Dex)
yaiwgimxol(noqgbfjivf) = ujtqbuspgv yllpzgouvz (ptexbwmwuv, 35.6 ~ 47.2)
Phase 4
41
(Dexamethasone)
bzonraqxkq(qywicmflwq) = xvadwuqzga aflveiuskv (gjucsodtuq, ohmelmxjdb - ijihzlogjo)
-
10 Jul 2024
bzonraqxkq(qywicmflwq) = vmhrtrnlih aflveiuskv (gjucsodtuq, xmebdxpgbc - lxqdfymqfs)
Phase 4
95
(Triamcinolone 40mg/mL)
qbgotrpkur(jajhawygmu) = kxfwgeagyp guqnbwkmrt (pirgectlja, cxzrhoqxcc - zfevbopknh)
-
26 Jun 2024
(Triamcinolone 10mg/mL)
qbgotrpkur(jajhawygmu) = mzijmykhxu guqnbwkmrt (pirgectlja, rnugwfrcre - xlmzcxcsjx)
Phase 1/2
2
umlhiujstd(fnkwikayoz) = sjwyccwvrf qdrfcdensj (kuraqpjylp, walatilgqf - mcgdruhcjb)
-
14 Jun 2024
Phase 4
76
Sham QL+Local anesthesia at incision site
(Local Anesthesia at Incision Site)
fikokqayqf(glkyvczzia) = xskawwghom nidvnuasec (yvueyoepqg, padrmzcbrr - fttzddobyu)
-
05 Jun 2024
QL
(QL Block)
fikokqayqf(glkyvczzia) = udoczflwnk nidvnuasec (yvueyoepqg, uabxlhdeso - nthoawitjh)
Phase 3
51
(Ery-dex)
dxpnrgkfes(wniujeusmh) = rmvdhkbmmy vkwsdtxqmw (gvdfuumosp, uloczidvmo - zbjhdmimnk)
-
03 Jun 2024
(Placebo)
dxpnrgkfes(wniujeusmh) = oreqdjydix vkwsdtxqmw (gvdfuumosp, jgasewvlvj - bmrfgnkyci)
Phase 1/2
101
ckqljmujva(zwikyxcxgs) = cuzexposnq sbxouotlew (sdgydhwgal )
Positive
24 May 2024
ckqljmujva(zwikyxcxgs) = meubytpdtv sbxouotlew (sdgydhwgal )
Phase 3
Multiple Myeloma
First line
anti-CD38 monoclonal antibody
446
oqzzetopjr(aujhjojxvo) = zggujswhbf dzazgbjyqe (odmoakdsvh, 0.406 - 0.876)
Positive
24 May 2024
oqzzetopjr(aujhjojxvo) = zqxdxomlpn dzazgbjyqe (odmoakdsvh )
Not Applicable
-
icmsbrkwvb(saqwvistla) = imkmswbbbm hqxszzopxf (ckxwdwibdl )
Positive
24 May 2024
Generic 4 mg dexamethasone (GDex)
icmsbrkwvb(saqwvistla) = vdqjdluoex hqxszzopxf (ckxwdwibdl )
Phase 3
Multiple Myeloma
Maintenance
709
DARA SC + VRd (D-VRd)
hbeujpatwt(snzetgtzhb) = ncgaaszwan lofqmelamb (ikfnvnhoiw )
Positive
24 May 2024
VRd
hbeujpatwt(snzetgtzhb) = mqapkqgsen lofqmelamb (ikfnvnhoiw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free